BERKELEY, CA -- (Marketwired) -- 03/17/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present data at the American Association for Cancer Research Annual Meeting next month in New Orleans, Louisiana. The details for the poster presentations are as follows:
Date and Time: Monday, April 18, 2016, 1:00 p.m. - 5:00 p.m. EDT
Abstract Title: SD-101, a novel intratumoral class C CpG-ODN, given with low-dose radiation in patients with untreated low-grade B-cell lymphoma: interim results of a phase I trial
Session Title: Phase I Clinical Trials 1
Abstract Control Number: 7361
Permanent Abstract Number: CT047
Location: Convention Center, Halls G-J, Poster Section 13
Poster Board Number: 3
Please click here for the full abstract. The poster presentation with updated data will be made available on or after April 18, 2016.
Date and Time: Monday, April 18, 2016, 1:00 p.m. - 5:00 p.m. EDT
Abstract Title: Intratumoral treatment with a highly interferogenic TLR9 agonist reverts tumor escape from PD-1 blockade
Session Title: Immune Checkpoints 1
Abstract Control Number: 4045
Permanent Abstract Number: 2322
Location: Convention Center, Halls G-J, Poster Section 26
Please click here for the full abstract. The poster presentation with updated data will be made available on or after April 18, 2016.
Date and Time: Wednesday April 20, 2016, 8:00 a.m. - 12:00 p.m. EDT
Abstract Title: Radiation potentiates systemic anti-tumor immunity unleashed by a novel TLR9 agonist (SD-101)
Session Title: Immune Modulation from Non-Immunotherapy and Antibodies: Clinical
Abstract Number: 4985
Location: Convention Center, Halls G-J, Poster Section 26
Poster Board Number: 9
Please click here for the full abstract. The poster presentation with updated data will be made available on or after April 20, 2016.
About SD-101
SD-101, the subject of AACR abstracts CT047, 2322 and 4985, is Dynavax’s proprietary, second-generation, CpG-C class oligodeoxynucleotide TLR 9 agonist. SD-101 activates multiple anti-tumor mechanisms of innate immune cells and activates plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and induce high levels of Type I interferons and maturation of plasmacytoid dendritic cells and B cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its preliminary safety and activity.
About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious diseases and oncology. Dynavax’s lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit www.dynavax.com.
